A group of radiologists from Boston Medical Center is using interventional techniques to treat bleeding Jehovah’s Witness patients.
A group of radiologists from Boston Medical Center is using interventional techniques to treat bleeding Jehovah's Witness patients.
The Jehovah's Witness (JW) movement was established by Charles Russell in Pennsylvania in the 1870s and now has six million followers worldwide. Issues with blood transfusions were first described in the July 1945 edition of The Watchtower, the movement's official publication. Followers believe ingestion of blood can result in loss of eternal life, eternal damnation, and excommunication from their congregation. Many also believe that individuals offering to transfuse blood are acting through the devil's influence.
Acceptable medical treatments for JWs include most surgical/interventional procedures and anesthesiologic blood conservation methods, as well as diagnostic and therapeutic procedures, synthetic oxygen therapeutics, non-blood volume expanders, pharmacologic agents that do not contain blood components or fractions such as vasoconstrictors, agents that enhance hematopoiesis, and recombinant products, said Dr. Nii-Kabu Kabutey, lead author of the Boston group's RSNA 09 education exhibit.
Other procedures that are acceptable to some JWs include apheresis, hemodialysis, plasma-derived fractions (immunoglobulins, vaccines, antivenins, albumin, cryoprecipitate), hemostatic products containing blood fractions (fibrin glue and/or sealant), and hemostatic bandages containing plasma fractions and thrombin sealants.
Many JWs have problems finding a physician who will treat them in accordance with their beliefs, and they fear their beliefs would not be respected during a medical emergency. Conversely, some physicians think these beliefs are at odds with their duty to promote a patient's well being, according to Kabutey.
Before a procedure, the Boston Medical Center team evaluates the patient's history of bleeding or previous hematologic or thrombotic disorders, plus the individual's family history in this area. Members of the team then obtain a modified informed consent, aggressively treat anemia, work to minimize iatrogenic blood loss and the number of blood samples taken, and use pediatric tubes. They use various techniques to limit blood loss and reduce transfusion requirements, including meticulous hemostasis and use of closure devices to the puncture site, good manual compression at the puncture site, and reverse anticoagulation if clinically feasible.
After the procedure, further methods are used to reduce blood loss, such as close clinical follow-up, minimizing oxygen consumption, and maximizing oxygen saturation.
"Understanding the social and clinical challenges in the treatment of JW patients is essential to provide quality care," Kabutey said. "Proper preprocedural planning can improve the outcome of interventional procedures on bleeding JW patients."
One of the group's success stories was a 57-year-old JW woman with an acute onset of bright red blood per rectum. A colonoscopy did not reveal any abnormal pathology. Embolization of the right colonic artery was successful, and the patient did not require a transfusion or surgical intervention. In another case, a 33-year-old female JW presented acutely with postpartum hemorrhage. She refused a transfusion and wanted to avoid a hysterectomy. Bilateral embolization of uterine arteries was accomplished with Gelfoam. Her bleeding stopped after the procedure, and she did not require a hysterectomy.
AI Facilitates Nearly 83 Percent Improvement in Turnaround Time for Fracture X-Rays
December 19th 2023In addition to offering a 98.5 percent sensitivity rate in diagnosing fractures on X-ray, an emerging artificial intelligence (AI) software reportedly helped reduce mean turnaround time on X-ray fracture diagnosis from 48 hours to 8.3 hours, according to new research presented at the Radiological Society of North America (RSNA) conference.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Can an Emerging PET Radiotracer Enhance Detection of Prostate Cancer Recurrence?
December 14th 2023The use of 68Ga-RM2 PET/MRI demonstrated a 35 percent higher sensitivity rate than MRI alone for the diagnosis of biochemical recurrence of prostate cancer, according to research recently presented at the Radiological Society of North America (RSNA) conference.
RSNA 2020: Addressing Healthcare Disparities and Access to Care
December 4th 2020Rich Heller, M.D., with Radiology Partners, and Lucy Spalluto, M.D., with Vanderbilt University School of Medicine, discuss the highlights of their RSNA 2020 session on health disparities, focusing on the underlying factors and challenges radiologists face to providing greater access to care.
Can AI Improve Detection of Extraprostatic Extension on MRI?
December 4th 2023Utilizing a deep learning-based AI algorithm to differentiate between diagnostic and non-diagnostic quality of prostate MRI facilitated a 10 percent higher specificity rate for diagnosing extraprostatic extension on multiparametric MRI, according to research presented at the recent RSNA conference.
Study: Regular Mammography Screening Reduces Breast Cancer Mortality Risk by More than 70 Percent
November 30th 2023Consistent adherence to the five most recent mammography screenings prior to a breast cancer diagnosis reduced breast cancer death risk by 72 percent in comparison to women who did not have the mammography screening, according to new research findings presented at the annual Radiological Society of North America (RSNA) conference.